首页 > 最新文献

Biomarker Insights最新文献

英文 中文
Copeptin Reflect Left Ventricular Systolic Function at Early Stage of Acute Myocardial Infarction in a Pig Model. Copeptin反映猪急性心肌梗死模型早期左心室收缩功能。
IF 3.8 Q2 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2023-01-01 DOI: 10.1177/11772719231171764
Wenjia Li, Wenjian Sun, Liang Lyu, Gang Wang, Weixin Yang, Hongfei An, Liling Chen, Jianhui Fan, Yan Yue, Rongshun Zhang

Introduction: Measurement of biomarkers early after acute myocardial infarction (AMI) might provide a cost-effective and widely available tool to assess infarct severity, myocardial dysfunction, and clinical outcomes. We aimed to induce AMI in miniature pigs, measure the levels of serum biomarkers and global LV function dynamically and explore the release kinetics and optimal sampling time points of copeptin and its correlation with global LV function.

Methods: We induced AMI in the experimental group using a closed-chest model. Left ventricular (LV) function was detected by dual-source computed tomography (DSCT) and serum copeptin was determined by ELISA.

Results: The serum copeptin levels were increased at 1 hour, peaked at 3 hours, gradually decreased after 6 hours, and returned to baseline 3 days after AMI. At 3 to 6 hours, the copeptin cutoff of 16.97 to 17.44 pmol/l had 100% sensitivity and 100% specificity (P ⩽ .001) for AMI. Serum copeptin levels at 3 hours and 3 days were negatively correlated with the 3-hours LVEF (P ⩽ .001), respectively.

Conclusion: Serum copeptin levels change in time, and measurements at 3 to 6 hours after AMI had the highest predictive value.

急性心肌梗死(AMI)后早期生物标志物的测量可能为评估梗死严重程度、心肌功能障碍和临床结果提供一种经济有效且广泛可用的工具。本研究旨在诱导小型猪急性心肌梗死,动态测定血清生物标志物水平和整体左室功能,探讨copeptin的释放动力学、最佳采样时间点及其与整体左室功能的相关性。方法:采用闭胸模型对实验组进行AMI诱导。双源计算机断层扫描(DSCT)检测左心室功能,ELISA检测血清copeptin。结果:AMI患者血清copeptin水平在1小时时升高,3小时时达到峰值,6小时后逐渐下降,3天后恢复到基线水平。在3 ~ 6 h时,copeptin的临界值为16.97 ~ 17.44 pmol/l,对AMI具有100%的敏感性和100%的特异性(P < 0.001)。3 h和3 d时血清copeptin水平分别与3 h LVEF呈负相关(P < 0.001)。结论:血清copeptin水平随时间变化,AMI后3 ~ 6小时测定具有最高的预测价值。
{"title":"Copeptin Reflect Left Ventricular Systolic Function at Early Stage of Acute Myocardial Infarction in a Pig Model.","authors":"Wenjia Li,&nbsp;Wenjian Sun,&nbsp;Liang Lyu,&nbsp;Gang Wang,&nbsp;Weixin Yang,&nbsp;Hongfei An,&nbsp;Liling Chen,&nbsp;Jianhui Fan,&nbsp;Yan Yue,&nbsp;Rongshun Zhang","doi":"10.1177/11772719231171764","DOIUrl":"https://doi.org/10.1177/11772719231171764","url":null,"abstract":"<p><strong>Introduction: </strong>Measurement of biomarkers early after acute myocardial infarction (AMI) might provide a cost-effective and widely available tool to assess infarct severity, myocardial dysfunction, and clinical outcomes. We aimed to induce AMI in miniature pigs, measure the levels of serum biomarkers and global LV function dynamically and explore the release kinetics and optimal sampling time points of copeptin and its correlation with global LV function.</p><p><strong>Methods: </strong>We induced AMI in the experimental group using a closed-chest model. Left ventricular (LV) function was detected by dual-source computed tomography (DSCT) and serum copeptin was determined by ELISA.</p><p><strong>Results: </strong>The serum copeptin levels were increased at 1 hour, peaked at 3 hours, gradually decreased after 6 hours, and returned to baseline 3 days after AMI. At 3 to 6 hours, the copeptin cutoff of 16.97 to 17.44 pmol/l had 100% sensitivity and 100% specificity (<i>P</i> ⩽ .001) for AMI. Serum copeptin levels at 3 hours and 3 days were negatively correlated with the 3-hours LVEF (<i>P</i> ⩽ .001), respectively.</p><p><strong>Conclusion: </strong>Serum copeptin levels change in time, and measurements at 3 to 6 hours after AMI had the highest predictive value.</p>","PeriodicalId":47060,"journal":{"name":"Biomarker Insights","volume":"18 ","pages":"11772719231171764"},"PeriodicalIF":3.8,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/02/e7/10.1177_11772719231171764.PMC10155031.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10289659","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Implementation of a Customized Tertiary Analysis Platform for the Reporting of Somatic Variants. 体细胞变异报告定制三级分析平台的实现。
IF 3.8 Q2 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2023-01-01 DOI: 10.1177/11772719231178618
Kala F Schilter, Sarah Dubay, Matt Stachowiak, Alysia Kaplan, Abby Stauffenger, Honey V Reddi

Precision medicine for oncology requires the evaluation of variants identified in molecular profiling of solid tumors and hematologic malignancies. This includes evaluation of pre-analytical and postanalytical quality metrics, variant interpretation, classification, and tiering as outlined in established guidelines, association with clinical significance such as FDA approved drugs and clinical trials, and finally comprehensive reporting. This study documents our experience with the customization and implementation of a software platform that facilitates these requirements for effective reporting of somatic variants.

肿瘤精准医学需要对实体瘤和血液恶性肿瘤分子谱中识别的变异进行评估。这包括分析前和分析后质量指标的评估、变异解释、分类和分级,以及与临床意义(如FDA批准的药物和临床试验)的关联,最后是综合报告。这项研究记录了我们在定制和实现软件平台方面的经验,该软件平台促进了有效报告体细胞变异的这些需求。
{"title":"Implementation of a Customized Tertiary Analysis Platform for the Reporting of Somatic Variants.","authors":"Kala F Schilter,&nbsp;Sarah Dubay,&nbsp;Matt Stachowiak,&nbsp;Alysia Kaplan,&nbsp;Abby Stauffenger,&nbsp;Honey V Reddi","doi":"10.1177/11772719231178618","DOIUrl":"https://doi.org/10.1177/11772719231178618","url":null,"abstract":"<p><p>Precision medicine for oncology requires the evaluation of variants identified in molecular profiling of solid tumors and hematologic malignancies. This includes evaluation of pre-analytical and postanalytical quality metrics, variant interpretation, classification, and tiering as outlined in established guidelines, association with clinical significance such as FDA approved drugs and clinical trials, and finally comprehensive reporting. This study documents our experience with the customization and implementation of a software platform that facilitates these requirements for effective reporting of somatic variants.</p>","PeriodicalId":47060,"journal":{"name":"Biomarker Insights","volume":"18 ","pages":"11772719231178618"},"PeriodicalIF":3.8,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/63/ba/10.1177_11772719231178618.PMC10259170.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9686203","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Identification of Potential Urinary Metabolite Biomarkers of Pseudomonas aeruginosa Ventilator-Associated Pneumonia 铜绿假单胞菌呼吸机相关性肺炎潜在尿液代谢物生物标志物的鉴定
IF 3.8 Q2 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2022-01-01 DOI: 10.1177/11772719221099131
B. Jongers, A. Hotterbeekx, Kenny Bielen, P. Vervliet, J. Boddaert, C. Lammens, E. Fransen, G. Baggerman, A. Covaci, H. Goossens, S. Malhotra-Kumar, P. Jorens, S. Kumar-Singh
Introduction: Ventilator-associated pneumonia (VAP) caused by Pseudomonas aeruginosa is a major cause of morbidity and mortality in hospital intensive care units (ICU). Rapid identification of P. aeruginosa-derived markers in easily accessible patients’ samples can enable an early detection of P. aeruginosa VAP (VAP-PA), thereby stewarding antibiotic use and improving clinical outcomes. Methods: Metabolites were analysed using liquid chromatography-mass spectrometry (LC-MS) in prospectively collected urine samples from mechanically ventilated patients admitted to the Antwerp University Hospital ICU. Patients were followed from the start of mechanical ventilation (n = 100 patients) till the time of clinical diagnosis of VAP (n = 13). Patients (n = 8) in whom diagnosis of VAP was further confirmed by culturing respiratory samples and urine samples were studied for semi-quantitative metabolomics. Results: We first show that multivariate analyses highly discriminated VAP-PA from VAP–non-PA as well as from the pre-infection groups (R2 = .97 and .98, respectively). A further univariate analysis identified 58 metabolites that were significantly elevated or uniquely present in VAP-PA compared to the VAP–non-PA and pre-infection groups (P < .05). These comprised both a known metabolite of histidine as well as a novel nicotine metabolite. Most interestingly, we identified 3 metabolites that were not only highly upregulated for, but were also highly specific to, VAP-PA, as these metabolites were completely absent in all pre-infection timepoints and in VAP–non-PA group. Conclusions: Considerable differences exist between urine metabolites in VAP-PA compared to VAP due to other bacterial aetiologies as well to non-VAP (pre-infection) timepoints. The unique urinary metabolic biomarkers we describe here, if further validated, could serve as highly specific diagnostic biomarkers of VAP-PA.
由铜绿假单胞菌引起的呼吸机相关性肺炎(VAP)是医院重症监护病房(ICU)发病和死亡的主要原因。在易于获取的患者样本中快速鉴定铜绿假单胞菌衍生的标记物可以早期发现铜绿假单胞菌VAP (VAP- pa),从而管理抗生素的使用并改善临床结果。方法:采用液相色谱-质谱联用(LC-MS)对安特卫普大学医院ICU收治的机械通气患者前瞻性尿液样本进行代谢物分析。随访患者从机械通气开始(n = 100例)至临床诊断为VAP时(n = 13例)。通过培养呼吸样本和尿液样本进一步证实VAP诊断的患者(n = 8)进行半定量代谢组学研究。结果:我们首先发现多变量分析高度区分了VAP-PA与vap -非pa以及感染前组(R2 =。分别为97和0.98)。进一步的单变量分析发现,与vap -非pa组和感染前组相比,VAP-PA组中58种代谢物显著升高或仅存在(P < 0.05)。这包括一种已知的组氨酸代谢物和一种新的尼古丁代谢物。最有趣的是,我们发现了3种代谢物,它们不仅对VAP-PA高度上调,而且对VAP-PA高度特异性,因为这些代谢物在所有感染前时间点和vap -非pa组中完全不存在。结论:与VAP相比,由于其他细菌病因以及非VAP(感染前)时间点,VAP- pa尿液代谢物存在相当大的差异。我们在这里描述的独特的尿液代谢生物标志物,如果进一步验证,可以作为高度特异性的VAP-PA诊断生物标志物。
{"title":"Identification of Potential Urinary Metabolite Biomarkers of Pseudomonas aeruginosa Ventilator-Associated Pneumonia","authors":"B. Jongers, A. Hotterbeekx, Kenny Bielen, P. Vervliet, J. Boddaert, C. Lammens, E. Fransen, G. Baggerman, A. Covaci, H. Goossens, S. Malhotra-Kumar, P. Jorens, S. Kumar-Singh","doi":"10.1177/11772719221099131","DOIUrl":"https://doi.org/10.1177/11772719221099131","url":null,"abstract":"Introduction: Ventilator-associated pneumonia (VAP) caused by Pseudomonas aeruginosa is a major cause of morbidity and mortality in hospital intensive care units (ICU). Rapid identification of P. aeruginosa-derived markers in easily accessible patients’ samples can enable an early detection of P. aeruginosa VAP (VAP-PA), thereby stewarding antibiotic use and improving clinical outcomes. Methods: Metabolites were analysed using liquid chromatography-mass spectrometry (LC-MS) in prospectively collected urine samples from mechanically ventilated patients admitted to the Antwerp University Hospital ICU. Patients were followed from the start of mechanical ventilation (n = 100 patients) till the time of clinical diagnosis of VAP (n = 13). Patients (n = 8) in whom diagnosis of VAP was further confirmed by culturing respiratory samples and urine samples were studied for semi-quantitative metabolomics. Results: We first show that multivariate analyses highly discriminated VAP-PA from VAP–non-PA as well as from the pre-infection groups (R2 = .97 and .98, respectively). A further univariate analysis identified 58 metabolites that were significantly elevated or uniquely present in VAP-PA compared to the VAP–non-PA and pre-infection groups (P < .05). These comprised both a known metabolite of histidine as well as a novel nicotine metabolite. Most interestingly, we identified 3 metabolites that were not only highly upregulated for, but were also highly specific to, VAP-PA, as these metabolites were completely absent in all pre-infection timepoints and in VAP–non-PA group. Conclusions: Considerable differences exist between urine metabolites in VAP-PA compared to VAP due to other bacterial aetiologies as well to non-VAP (pre-infection) timepoints. The unique urinary metabolic biomarkers we describe here, if further validated, could serve as highly specific diagnostic biomarkers of VAP-PA.","PeriodicalId":47060,"journal":{"name":"Biomarker Insights","volume":" ","pages":""},"PeriodicalIF":3.8,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46598480","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Advantages and Limitations of Monitoring Circulating Tumor DNA Levels to Predict the Prognosis of Patients Diagnosed With Gastric Cancer. 监测循环肿瘤DNA水平预测胃癌患者预后的优势与局限性。
IF 3.8 Q2 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2022-01-01 DOI: 10.1177/11772719221141525
Wan He, Jingxin Yang, Xiao Sun, Shunda Jiang, Jinchan Jiang, Ming Liu, Tianhao Mu, Yingmei Li, Xiaoni Zhang, Jingxian Duan, Ruilian Xu

Next-generation sequencing-based genomic profiling facilitates biomarker detection by cell-free DNA (cfDNA) liquid biopsy. However, the efficiency of mutation calling and the prognostic value of cfDNA biomarkers are disputed. We investigated 24 patients with gastric cancer in this study, using a 605-gene sequencing panel to sequence their plasma cfDNA and tumor tissue DNA. The mutation concordance between plasma cfDNA and tumor tissue DNA was 70.6% in stage IV gastric cancer and 30.2% in stage III gastric cancer, indicating insufficient mutation detection rates in stage III and early-stage cancer. When compared with total cfDNA load and blood tumor mutation burden (bTMB), the variant allele frequencies (VAF) of commonly mutated genes are highly accurate in representing disease burden. Further, VAF are a better prognostic indicator compared with serum biomarkers including carcinoembryonic antigen (CEA), carbohydrate antigen 19-9 (CA19-9), cancer antigen 125 (CA125), and alpha-fetoprotein (AFP). The use of cfDNA in molecular profiling of patients allows prediction of patient survival and clinical response, as well as the development of personalized therapy regimens.

下一代基于测序的基因组图谱有助于通过无细胞DNA (cfDNA)液体活检检测生物标志物。然而,突变召唤的效率和cfDNA生物标志物的预后价值存在争议。在本研究中,我们调查了24例胃癌患者,使用605基因测序板对其血浆cfDNA和肿瘤组织DNA进行测序。血浆cfDNA与肿瘤组织DNA的突变一致性在IV期胃癌中为70.6%,在III期胃癌中为30.2%,表明在III期和早期癌症中突变检出率不足。与总cfDNA负荷和血液肿瘤突变负荷(bTMB)相比,常见突变基因的变异等位基因频率(VAF)在表征疾病负担方面具有较高的准确性。此外,与癌胚抗原(CEA)、碳水化合物抗原19-9 (CA19-9)、癌抗原125 (CA125)和甲胎蛋白(AFP)等血清生物标志物相比,VAF是一个更好的预后指标。在患者分子谱分析中使用cfDNA可以预测患者的生存和临床反应,以及制定个性化的治疗方案。
{"title":"Advantages and Limitations of Monitoring Circulating Tumor DNA Levels to Predict the Prognosis of Patients Diagnosed With Gastric Cancer.","authors":"Wan He,&nbsp;Jingxin Yang,&nbsp;Xiao Sun,&nbsp;Shunda Jiang,&nbsp;Jinchan Jiang,&nbsp;Ming Liu,&nbsp;Tianhao Mu,&nbsp;Yingmei Li,&nbsp;Xiaoni Zhang,&nbsp;Jingxian Duan,&nbsp;Ruilian Xu","doi":"10.1177/11772719221141525","DOIUrl":"https://doi.org/10.1177/11772719221141525","url":null,"abstract":"<p><p>Next-generation sequencing-based genomic profiling facilitates biomarker detection by cell-free DNA (cfDNA) liquid biopsy. However, the efficiency of mutation calling and the prognostic value of cfDNA biomarkers are disputed. We investigated 24 patients with gastric cancer in this study, using a 605-gene sequencing panel to sequence their plasma cfDNA and tumor tissue DNA. The mutation concordance between plasma cfDNA and tumor tissue DNA was 70.6% in stage IV gastric cancer and 30.2% in stage III gastric cancer, indicating insufficient mutation detection rates in stage III and early-stage cancer. When compared with total cfDNA load and blood tumor mutation burden (bTMB), the variant allele frequencies (VAF) of commonly mutated genes are highly accurate in representing disease burden. Further, VAF are a better prognostic indicator compared with serum biomarkers including carcinoembryonic antigen (CEA), carbohydrate antigen 19-9 (CA19-9), cancer antigen 125 (CA125), and alpha-fetoprotein (AFP). The use of cfDNA in molecular profiling of patients allows prediction of patient survival and clinical response, as well as the development of personalized therapy regimens.</p>","PeriodicalId":47060,"journal":{"name":"Biomarker Insights","volume":"17 ","pages":"11772719221141525"},"PeriodicalIF":3.8,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/33/80/10.1177_11772719221141525.PMC9751168.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10406501","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Utilization of Prognostic Biomarker Soluble Urokinase Plasminogen Activator Receptor in the Emergency Department: A Tool for Safe and More Efficient Decision-making 预后生物标志物可溶性尿激酶纤溶酶原激活剂受体在急诊科的应用:一种安全高效的决策工具
IF 3.8 Q2 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2022-01-01 DOI: 10.1177/11772719221081789
Ria M Holstein, M. Mäkinen, M. Castrén, J. Kaartinen
Introduction: Risk stratification in the emergency departments (EDs) is in critical need for new applications due to ED overcrowding and hospitalization of older people. We aimed to evaluate the expediency, efficiency and safety of a prognostic biomarker, soluble urokinase plasminogen activator receptor (suPAR), as a tool for the risk assessment of patients arriving at the ED. Methods: We performed a comparative cross-sectional study in 2 emergency departments (EDs), suPAR measurements being incorporated into routine blood sampling in the intervention ED. The primary outcome was the number of discharges from the ED. The importance of the outcomes was examined by appropriate multi- or bivariate analysis. Results: The absolute and relative number of discharges were similar between the intervention and control groups [121 (55.3%) vs 62 (55.9%)]. No significant differences between the groups were seen in the length of stays in the ED. Patients with low suPAR values were more likely discharged and patients with high suPAR values more likely admitted to hospital. Two admitted patients with low suPAR values could have been discharged safely. Conclusion: The utilization of suPAR did not increase the risk for neither positive nor negative outcomes. Low suPAR values could be potential in discharging more patients safely. Instead of unselected patient populations, the benefits of suPAR measurements in the ED could emerge in the assessment of a more precisely determined and selected group of patients.
导读:由于急诊科过度拥挤和老年人住院,急诊科的风险分层急需新的应用。我们的目的是评估一种预后生物标志物,可溶性尿激酶纤溶酶原激活物受体(suPAR)作为急诊科患者风险评估工具的便利性、有效性和安全性。我们在2个急诊科(ED)进行了一项比较横断面研究,suPAR测量被纳入干预急诊科的常规血液采样。主要结果是急诊科的出院人数。通过适当的多变量或双变量分析来检验结果的重要性。结果:干预组和对照组的绝对出院数和相对出院数相似[121例(55.3%)比62例(55.9%)]。两组患者在急诊科的住院时间没有显著差异。suPAR值低的患者更有可能出院,suPAR值高的患者更有可能住院。两名suPAR值较低的住院患者本可以安全出院。结论:使用suar不会增加阳性和阴性结果的风险。低suPAR值可能有助于更多患者安全出院。代替未选择的患者群体,suPAR测量在急诊科的好处可以出现在更精确确定和选择的患者群体的评估中。
{"title":"Utilization of Prognostic Biomarker Soluble Urokinase Plasminogen Activator Receptor in the Emergency Department: A Tool for Safe and More Efficient Decision-making","authors":"Ria M Holstein, M. Mäkinen, M. Castrén, J. Kaartinen","doi":"10.1177/11772719221081789","DOIUrl":"https://doi.org/10.1177/11772719221081789","url":null,"abstract":"Introduction: Risk stratification in the emergency departments (EDs) is in critical need for new applications due to ED overcrowding and hospitalization of older people. We aimed to evaluate the expediency, efficiency and safety of a prognostic biomarker, soluble urokinase plasminogen activator receptor (suPAR), as a tool for the risk assessment of patients arriving at the ED. Methods: We performed a comparative cross-sectional study in 2 emergency departments (EDs), suPAR measurements being incorporated into routine blood sampling in the intervention ED. The primary outcome was the number of discharges from the ED. The importance of the outcomes was examined by appropriate multi- or bivariate analysis. Results: The absolute and relative number of discharges were similar between the intervention and control groups [121 (55.3%) vs 62 (55.9%)]. No significant differences between the groups were seen in the length of stays in the ED. Patients with low suPAR values were more likely discharged and patients with high suPAR values more likely admitted to hospital. Two admitted patients with low suPAR values could have been discharged safely. Conclusion: The utilization of suPAR did not increase the risk for neither positive nor negative outcomes. Low suPAR values could be potential in discharging more patients safely. Instead of unselected patient populations, the benefits of suPAR measurements in the ED could emerge in the assessment of a more precisely determined and selected group of patients.","PeriodicalId":47060,"journal":{"name":"Biomarker Insights","volume":"17 1","pages":""},"PeriodicalIF":3.8,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44637318","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Immune Checkpoint Inhibitors in Triple Negative Breast Cancer: The Search for the Optimal Biomarker 癌症三阴性患者的免疫检查点抑制剂:寻找最佳生物标志物
IF 3.8 Q2 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2022-01-01 DOI: 10.1177/11772719221078774
SA Qureshi, N. Chan, Mridula A. George, S. Ganesan, D. Toppmeyer, C. Omene
Triple negative breast cancer (TNBC) is a high-risk and aggressive malignancy characterized by the absence of estrogen receptors (ER) and progesterone receptors (PR) on the surface of malignant cells, and by the lack of overexpression of human epidermal growth factor 2 (HER2). It has limited therapeutic options compared to other subtypes of breast cancer. There is now a growing body of evidence on the role of immunotherapy in TNBC, however much of the data from clinical trials is conflicting and thus, challenging for clinicians to integrate the data into clinical practice. Landmark phase III trials using immunotherapy in the early-stage neoadjuvant setting concluded that the addition of immunotherapy to chemotherapy improved the pathologic complete response (pCR) rate compared to chemotherapy with placebo while others found no significant improvement in pCR. Phase III trials have investigated the utility of immunotherapy in previously untreated metastatic TNBC, and these studies have similarly arrived at inconsistent conclusions. Some studies showed no benefit while others demonstrated a clinically significant improvement in overall survival in the PD-L1 positive population. It is not yet clear which biomarkers are most useful, and assays for these biomarkers have not been standardized. Given the often serious and severe side effects of immunotherapy, it is important and necessary to identify predictive biomarkers of response and resistance in order to enhance patient selection. In this review, we will discuss both the challenges of traditional biomarkers and the opportunities of emerging biomarkers for patient selection.
三阴性乳腺癌(TNBC)是一种高风险、侵袭性的恶性肿瘤,其特征是恶性细胞表面缺乏雌激素受体(ER)和孕激素受体(PR),并且缺乏人表皮生长因子2 (HER2)的过表达。与其他亚型乳腺癌相比,它的治疗选择有限。现在有越来越多的证据表明免疫治疗在TNBC中的作用,然而,临床试验的许多数据是相互矛盾的,因此,临床医生将这些数据整合到临床实践中是一项挑战。在早期新辅助治疗中使用免疫治疗的里程碑式III期试验得出结论,与安慰剂化疗相比,在化疗中添加免疫治疗可提高病理完全缓解率(pCR),而其他试验则发现pCR无显著改善。III期试验研究了免疫疗法对先前未治疗的转移性TNBC的效用,这些研究同样得出了不一致的结论。一些研究显示没有益处,而另一些研究显示PD-L1阳性人群的总生存率有临床显着改善。目前尚不清楚哪些生物标记物最有用,对这些生物标记物的测定也没有标准化。鉴于免疫治疗的严重副作用,确定反应和耐药的预测性生物标志物以增强患者选择是重要和必要的。在这篇综述中,我们将讨论传统生物标志物的挑战和新兴生物标志物在患者选择方面的机遇。
{"title":"Immune Checkpoint Inhibitors in Triple Negative Breast Cancer: The Search for the Optimal Biomarker","authors":"SA Qureshi, N. Chan, Mridula A. George, S. Ganesan, D. Toppmeyer, C. Omene","doi":"10.1177/11772719221078774","DOIUrl":"https://doi.org/10.1177/11772719221078774","url":null,"abstract":"Triple negative breast cancer (TNBC) is a high-risk and aggressive malignancy characterized by the absence of estrogen receptors (ER) and progesterone receptors (PR) on the surface of malignant cells, and by the lack of overexpression of human epidermal growth factor 2 (HER2). It has limited therapeutic options compared to other subtypes of breast cancer. There is now a growing body of evidence on the role of immunotherapy in TNBC, however much of the data from clinical trials is conflicting and thus, challenging for clinicians to integrate the data into clinical practice. Landmark phase III trials using immunotherapy in the early-stage neoadjuvant setting concluded that the addition of immunotherapy to chemotherapy improved the pathologic complete response (pCR) rate compared to chemotherapy with placebo while others found no significant improvement in pCR. Phase III trials have investigated the utility of immunotherapy in previously untreated metastatic TNBC, and these studies have similarly arrived at inconsistent conclusions. Some studies showed no benefit while others demonstrated a clinically significant improvement in overall survival in the PD-L1 positive population. It is not yet clear which biomarkers are most useful, and assays for these biomarkers have not been standardized. Given the often serious and severe side effects of immunotherapy, it is important and necessary to identify predictive biomarkers of response and resistance in order to enhance patient selection. In this review, we will discuss both the challenges of traditional biomarkers and the opportunities of emerging biomarkers for patient selection.","PeriodicalId":47060,"journal":{"name":"Biomarker Insights","volume":" ","pages":""},"PeriodicalIF":3.8,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47216587","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 10
The Availability of Human Biospecimens to Support Biomarker Research 支持生物标志物研究的人类生物标本的可用性
IF 3.8 Q2 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2022-01-01 DOI: 10.1177/11772719221091750
T. Tarling, J. Byrne, Peter H. Watson
Preserved biospecimens held in biobank inventories and clinical archives are important resources for biomarker research. Recent advances in technologies have led to an increase in use of clinical archives in particular, in order to study retrospective cohorts and to generate data relevant to tissue biomarkers. This raises the question of whether the current sizes of biobank inventories are appropriate to meet the demands of biomarker research. This commentary discusses this question by considering data concerning overall biobank and biospecimen numbers to estimate current biospecimen supply and use. The data suggests that biospecimen supply exceeds current demand. Therefore, it may be important for individual biobanks to reassess the targets for their inventories, consider culling unused portions of these inventories, and shift resources towards providing prospective custom biobanking services.
生物库库存和临床档案中保存的生物样本是生物标志物研究的重要资源。最近的技术进步导致了临床档案的使用增加,特别是为了研究回顾性队列和生成与组织生物标志物相关的数据。这就提出了一个问题,即目前的生物库库存规模是否适合满足生物标志物研究的需求。这篇评论通过考虑有关整体生物库和生物样本数量的数据来讨论这个问题,以估计当前的生物样本供应和使用。数据表明,生物样本的供应超过了目前的需求。因此,个体生物库重新评估其库存目标,考虑剔除这些库存中未使用的部分,并将资源转移到提供潜在的定制生物库服务上,这一点可能很重要。
{"title":"The Availability of Human Biospecimens to Support Biomarker Research","authors":"T. Tarling, J. Byrne, Peter H. Watson","doi":"10.1177/11772719221091750","DOIUrl":"https://doi.org/10.1177/11772719221091750","url":null,"abstract":"Preserved biospecimens held in biobank inventories and clinical archives are important resources for biomarker research. Recent advances in technologies have led to an increase in use of clinical archives in particular, in order to study retrospective cohorts and to generate data relevant to tissue biomarkers. This raises the question of whether the current sizes of biobank inventories are appropriate to meet the demands of biomarker research. This commentary discusses this question by considering data concerning overall biobank and biospecimen numbers to estimate current biospecimen supply and use. The data suggests that biospecimen supply exceeds current demand. Therefore, it may be important for individual biobanks to reassess the targets for their inventories, consider culling unused portions of these inventories, and shift resources towards providing prospective custom biobanking services.","PeriodicalId":47060,"journal":{"name":"Biomarker Insights","volume":" ","pages":""},"PeriodicalIF":3.8,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46273835","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Lack of Association of rs12702634 in RPA3-UMAD1 With Interstitial Lung Diseases in Japanese Rheumatoid Arthritis Patients RPA3-UMAD1中rs12702634与日本类风湿性关节炎患者间质性肺疾病缺乏相关性
IF 3.8 Q2 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2022-01-01 DOI: 10.1177/11772719221091758
Takashi Higuchi, S. Oka, H. Furukawa, K. Shimada, S. Tohma
Background: Rheumatoid arthritis (RA) is occasionally complicated with interstitial lung disease (ILD). A recent genome-wide association study of ILD in RA reported an association with the polymorphism rs12702634 in RPA3-UMAD1. We conducted an association study of this variant with ILD in Japanese RA patients to replicate this association. Methods: Genotyping of rs12702634 was performed in 175 RA with ILD and 411 RA without chronic lung disease. Results: No association was detected for rs12702634 with ILD in RA (P = .6369, odds ratio [OR] 1.13, 95% confidence interval [CI] 0.72-1.78). Meta-analysis of these data combined with the data from the recent report showed no significant association (P = .0996, OR 1.52, 95% CI 0.92–2.49). Conclusions: The present study demonstrated no association of RPA3-UMAD1 rs12702634 with ILD in RA, suggesting the heterogeneity of the disease.
背景:类风湿性关节炎(RA)偶尔会并发间质性肺疾病(ILD)。最近的一项全基因组关联研究报告了RA中ILD与RPA3-UMAD1多态性rs12702634的关联。我们在日本RA患者中进行了一项该变异与ILD的关联研究,以重复这种关联。方法:对175例伴有ILD的RA和411例无慢性肺部疾病的RA进行rs12702634基因分型。结果:rs12702634与RA的ILD无相关性(P =。6369,优势比[OR] 1.13, 95%可信区间[CI] 0.72-1.78)。将这些数据与近期报告的数据进行meta分析,结果显示无显著相关性(P =。0.996,或1.52,95% ci 0.92-2.49)。结论:本研究显示RPA3-UMAD1 rs12702634与RA的ILD无关联,提示该疾病具有异质性。
{"title":"Lack of Association of rs12702634 in RPA3-UMAD1 With Interstitial Lung Diseases in Japanese Rheumatoid Arthritis Patients","authors":"Takashi Higuchi, S. Oka, H. Furukawa, K. Shimada, S. Tohma","doi":"10.1177/11772719221091758","DOIUrl":"https://doi.org/10.1177/11772719221091758","url":null,"abstract":"Background: Rheumatoid arthritis (RA) is occasionally complicated with interstitial lung disease (ILD). A recent genome-wide association study of ILD in RA reported an association with the polymorphism rs12702634 in RPA3-UMAD1. We conducted an association study of this variant with ILD in Japanese RA patients to replicate this association. Methods: Genotyping of rs12702634 was performed in 175 RA with ILD and 411 RA without chronic lung disease. Results: No association was detected for rs12702634 with ILD in RA (P = .6369, odds ratio [OR] 1.13, 95% confidence interval [CI] 0.72-1.78). Meta-analysis of these data combined with the data from the recent report showed no significant association (P = .0996, OR 1.52, 95% CI 0.92–2.49). Conclusions: The present study demonstrated no association of RPA3-UMAD1 rs12702634 with ILD in RA, suggesting the heterogeneity of the disease.","PeriodicalId":47060,"journal":{"name":"Biomarker Insights","volume":" ","pages":""},"PeriodicalIF":3.8,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47610435","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Cytokines in Abdominal Aortic Aneurysm: Master Regulators With Clinical Application 腹主动脉瘤中的细胞因子:主要调控因子及其临床应用
IF 3.8 Q2 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2022-01-01 DOI: 10.1177/11772719221095676
O. A. Puchenkova, V. Soldatov, Andrei E. Belykh, O. Bushueva, G. Piavchenko, Artem A Venediktov, N. Shakhpazyan, A. Deykin, M. Korokin, M. Pokrovskiy
Abdominal aortic aneurysm (AAA) is a potentially life-threatening disorder with a mostly asymptomatic course where the abdominal aorta is weakened and bulged. Cytokines play especially important roles (both positive and negative) among the molecular actors of AAA development. All the inflammatory cascades, extracellular matrix degradation and vascular smooth muscle cell apoptosis are driven by cytokines. Previous studies emphasize an altered expression and a changed epigenetic regulation of key cytokines in AAA tissue samples. Such cytokines as IL-6, IL-10, IL-12, IL-17, IL-33, IL-1β, TGF-β, TNF-α, IFN-γ, and CXCL10 seem to be crucial in AAA pathogenesis. Some data obtained in animal studies show a protective function of IL-10, IL-33, and canonical TGF-β signaling, as well as a dual role of IL-4, IFN-γ and CXCL10, while TNF-α, IL-1β, IL-6, IL-12/IL-23, IL-17, CCR2, CXCR2, CXCR4 and the TGF-β noncanonical pathway are believed to aggravate the disease. Altogether data highlight significance of cytokines as informative markers and predictors of AAA. Pathologic serum/plasma concentrations of IL-1β, IL-2, IL-6, TNF-α, IL-10, IL-8, IL-17, IFN-γ, and PDGF have been already found in AAA patients. Some of the changes correlate with the size of aneurysms. Moreover, the risk of AAA is associated with polymorphic variants of genes encoding cytokines and their receptors: CCR2 (rs1799864), CCR5 (Delta-32), IL6 (rs1800796 and rs1800795), IL6R (rs12133641), IL10 (rs1800896), TGFB1 (rs1800469), TGFBR1 (rs1626340), TGFBR2 (rs1036095, rs4522809, rs1078985), and TNFA (rs1800629). Finally, 5 single-nucleotide polymorphisms in gene coding latent TGF-β-binding protein (LTBP4) and an allelic variant of TGFB3 are related to a significantly slower AAA annual growth rate.
腹主动脉瘤(AAA)是一种潜在的危及生命的疾病,其病程大多为无症状,腹主动脉变弱和隆起。细胞因子在AAA发育的分子因子中起着特别重要的作用(阳性和阴性)。所有的炎症级联反应、细胞外基质降解和血管平滑肌细胞凋亡都是由细胞因子驱动的。先前的研究强调AAA组织样本中关键细胞因子的表达改变和表观遗传学调控改变。IL-6、IL-10、IL-12、IL-17、IL-33、IL-1β、TGF-β、TNF-α、IFN-γ和CXCL10等细胞因子似乎在AAA发病机制中至关重要。动物研究中获得的一些数据显示,IL-10、IL-33和经典TGF-β信号传导具有保护作用,以及IL-4、IFN-γ和CXCL10的双重作用,而TNF-α、IL-1β、IL-6、IL-12/IL-23、IL-17、CCR2、CXCR2、CXCR4和TGF-β非经典途径被认为会加重疾病。总之,数据强调了细胞因子作为AAA的信息标志物和预测因子的重要性。AAA患者的病理血清/血浆中已发现IL-1β、IL-2、IL-6、TNF-α、IL-10、IL-8、IL-17、IFN-γ和PDGF的浓度。其中一些变化与动脉瘤的大小有关。此外,AAA的风险与编码细胞因子及其受体的基因的多态性变体有关:CCR2(rs1799864)、CCR5(Delta-32)、IL6(rs1800796和rs1800795)、IL-6R(rs12133641)、IL10(rs1800896)、TGFB1(rs1800469)、TGFBR1(rs1626340)、TGFFR2(rs1036095、rs4522809、rs1078985)和TNFA(rs1800629)。最后,编码潜在TGF-β结合蛋白(LTBP4)的基因的5个单核苷酸多态性和TGFB3的一个等位基因变体与AAA年增长率显著减慢有关。
{"title":"Cytokines in Abdominal Aortic Aneurysm: Master Regulators With Clinical Application","authors":"O. A. Puchenkova, V. Soldatov, Andrei E. Belykh, O. Bushueva, G. Piavchenko, Artem A Venediktov, N. Shakhpazyan, A. Deykin, M. Korokin, M. Pokrovskiy","doi":"10.1177/11772719221095676","DOIUrl":"https://doi.org/10.1177/11772719221095676","url":null,"abstract":"Abdominal aortic aneurysm (AAA) is a potentially life-threatening disorder with a mostly asymptomatic course where the abdominal aorta is weakened and bulged. Cytokines play especially important roles (both positive and negative) among the molecular actors of AAA development. All the inflammatory cascades, extracellular matrix degradation and vascular smooth muscle cell apoptosis are driven by cytokines. Previous studies emphasize an altered expression and a changed epigenetic regulation of key cytokines in AAA tissue samples. Such cytokines as IL-6, IL-10, IL-12, IL-17, IL-33, IL-1β, TGF-β, TNF-α, IFN-γ, and CXCL10 seem to be crucial in AAA pathogenesis. Some data obtained in animal studies show a protective function of IL-10, IL-33, and canonical TGF-β signaling, as well as a dual role of IL-4, IFN-γ and CXCL10, while TNF-α, IL-1β, IL-6, IL-12/IL-23, IL-17, CCR2, CXCR2, CXCR4 and the TGF-β noncanonical pathway are believed to aggravate the disease. Altogether data highlight significance of cytokines as informative markers and predictors of AAA. Pathologic serum/plasma concentrations of IL-1β, IL-2, IL-6, TNF-α, IL-10, IL-8, IL-17, IFN-γ, and PDGF have been already found in AAA patients. Some of the changes correlate with the size of aneurysms. Moreover, the risk of AAA is associated with polymorphic variants of genes encoding cytokines and their receptors: CCR2 (rs1799864), CCR5 (Delta-32), IL6 (rs1800796 and rs1800795), IL6R (rs12133641), IL10 (rs1800896), TGFB1 (rs1800469), TGFBR1 (rs1626340), TGFBR2 (rs1036095, rs4522809, rs1078985), and TNFA (rs1800629). Finally, 5 single-nucleotide polymorphisms in gene coding latent TGF-β-binding protein (LTBP4) and an allelic variant of TGFB3 are related to a significantly slower AAA annual growth rate.","PeriodicalId":47060,"journal":{"name":"Biomarker Insights","volume":" ","pages":""},"PeriodicalIF":3.8,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49488601","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 10
Purpose, Partnership, and Possibilities: The Implementation of the Dog Aging Project Biobank. 目的、伙伴关系和可能性:狗衰老项目生物库的实施。
IF 3.8 Q2 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2022-01-01 DOI: 10.1177/11772719221137217
Lara Mouttham, Marta G Castelhano

Background: Biobanks have been supporting longitudinal prospective and retrospective studies by providing standardized services for the acquisition, transport, processing, storage, and distribution of high-quality biological material and associated data. Here, we describe how the Dog Aging Project (DAP), a large-scale longitudinal study of the domestic dog (Canis familiaris) with translational applications for humans, developed a biobank of canine biospecimens and associated data.

Design and methods: This was accomplished by working with the Cornell Veterinary Biobank, the first biobank in the world to receive accreditation to ISO 20387:2018-General Requirements for Biobanking. The biobank research team was involved in the early collection stages of the DAP, contributing to the development of appropriate workflows and processing fit-for-purpose biospecimens. In support of a dynamic strategy for real-time adjustment of processes, a pilot phase was implemented to develop, test, and optimize the biospecimen workflows, followed by an early phase of collection, processing, and banking of specimens from DAP participants.

Results: During the pilot and early phases of collection, the DAP Biobank stored 164 aliquots of whole blood, 273 aliquots of peripheral blood mononuclear cells, 130 aliquots of plasma, and 70 aliquots of serum, and extracted high molecular weight genomic DNA suitable for whole-genome sequencing from 109 whole blood specimens. These specimens, along with their associated preanalytical data, have been made available for distribution to researchers.

Conclusion: We discuss the challenges and opportunities encountered during the implementation of the DAP Biobank, along with novel strategies for promoting biobanking sustainability such as partnering with a DAP quality assurance manager and a DAP marketing and communication specialist and developing a pilot grant structure to fund small innovative research projects.

背景:生物银行通过为高质量生物材料和相关数据的获取、运输、处理、储存和分发提供标准化服务,支持纵向前瞻性和回顾性研究。在这里,我们描述了狗衰老项目(DAP),一个大规模的纵向研究家养狗(Canis familiaris)的翻译应用于人类,如何开发犬生物标本和相关数据的生物库。设计和方法:这是通过与康奈尔兽医生物库合作完成的,康奈尔兽医生物库是世界上第一个获得ISO 20387:2018-生物库一般要求认证的生物库。生物库研究小组参与了DAP的早期收集阶段,为制定适当的工作流程和处理适合用途的生物标本做出了贡献。为了支持实时调整流程的动态策略,实施了一个试点阶段,以开发、测试和优化生物标本工作流程,随后是早期阶段,收集、处理和储存DAP参与者的标本。结果:在前期和中试阶段,DAP Biobank共保存了164份全血、273份外周血单个核细胞、130份血浆和70份血清,并从109份全血标本中提取了适合全基因组测序的高分子量基因组DNA。这些标本及其相关的分析前数据已提供给研究人员分发。结论:我们讨论了DAP生物银行在实施过程中遇到的挑战和机遇,以及促进生物银行可持续性的新策略,如与DAP质量保证经理和DAP营销和沟通专家合作,以及制定试点资助结构来资助小型创新研究项目。
{"title":"Purpose, Partnership, and Possibilities: The Implementation of the Dog Aging Project Biobank.","authors":"Lara Mouttham,&nbsp;Marta G Castelhano","doi":"10.1177/11772719221137217","DOIUrl":"https://doi.org/10.1177/11772719221137217","url":null,"abstract":"<p><strong>Background: </strong>Biobanks have been supporting longitudinal prospective and retrospective studies by providing standardized services for the acquisition, transport, processing, storage, and distribution of high-quality biological material and associated data. Here, we describe how the Dog Aging Project (DAP), a large-scale longitudinal study of the domestic dog (<i>Canis familiaris</i>) with translational applications for humans, developed a biobank of canine biospecimens and associated data.</p><p><strong>Design and methods: </strong>This was accomplished by working with the Cornell Veterinary Biobank, the first biobank in the world to receive accreditation to ISO 20387:2018-General Requirements for Biobanking. The biobank research team was involved in the early collection stages of the DAP, contributing to the development of appropriate workflows and processing fit-for-purpose biospecimens. In support of a dynamic strategy for real-time adjustment of processes, a pilot phase was implemented to develop, test, and optimize the biospecimen workflows, followed by an early phase of collection, processing, and banking of specimens from DAP participants.</p><p><strong>Results: </strong>During the pilot and early phases of collection, the DAP Biobank stored 164 aliquots of whole blood, 273 aliquots of peripheral blood mononuclear cells, 130 aliquots of plasma, and 70 aliquots of serum, and extracted high molecular weight genomic DNA suitable for whole-genome sequencing from 109 whole blood specimens. These specimens, along with their associated preanalytical data, have been made available for distribution to researchers.</p><p><strong>Conclusion: </strong>We discuss the challenges and opportunities encountered during the implementation of the DAP Biobank, along with novel strategies for promoting biobanking sustainability such as partnering with a DAP quality assurance manager and a DAP marketing and communication specialist and developing a pilot grant structure to fund small innovative research projects.</p>","PeriodicalId":47060,"journal":{"name":"Biomarker Insights","volume":"17 ","pages":"11772719221137217"},"PeriodicalIF":3.8,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/05/fb/10.1177_11772719221137217.PMC9716607.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9635853","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Biomarker Insights
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1